Have a feature idea you'd love to see implemented?
Let us know!
LPTX Leap Therapeutics Inc
Price (delayed)
$2.36
Market cap
$90.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.74
Enterprise value
$11.01M
Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator.
Highlights
The EPS has surged by 73% year-on-year and by 18% since the previous quarter
LPTX's debt has dropped by 75% since the previous quarter but it is up by 2.6% year-on-year
The equity has grown by 39% since the previous quarter but it has declined by 22% year-on-year
The quick ratio is down by 36% year-on-year and by 5% since the previous quarter
Key stats
What are the main financial stats of LPTX
Market
Valuations
Earnings
Shares outstanding
38.26M
Market cap
$90.3M
Enterprise value
$11.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.37
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$60.11M
EBITDA
-$60.3M
Free cash flow
-$50.06M
Per share
Balance sheet
Liquidity
EPS
-$1.74
Free cash flow per share
-$1.28
Book value per share
$1.72
Revenue per share
$0
TBVPS
$2.08
Total assets
$81.43M
Total liabilities
$15.64M
Debt
$39,000
Equity
$65.79M
Working capital
$63.99M
Debt to equity
0
Current ratio
5.1
Quick ratio
5.17
Net debt/EBITDA
1.32
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-81.7%
Return on equity
-98.4%
Return on invested capital
N/A
Return on capital employed
-91.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LPTX stock price
How has the Leap Therapeutics stock price performed over time
Intraday
-1.67%
1 week
-3.67%
1 month
-16.31%
1 year
55.26%
YTD
-43.13%
QTD
-8.17%
Financial performance
How have Leap Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$65.73M
Net income
-$60.11M
Gross margin
N/A
Net margin
N/A
Leap Therapeutics's net income has increased by 27% YoY but it has decreased by 13% from the previous quarter
The company's operating income rose by 24% YoY but it fell by 11% QoQ
Growth
What is Leap Therapeutics's growth rate over time
Valuation
What is Leap Therapeutics stock price valuation
P/E
N/A
P/B
1.37
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 73% year-on-year and by 18% since the previous quarter
The equity has grown by 39% since the previous quarter but it has declined by 22% year-on-year
LPTX's P/B is 22% below its 5-year quarterly average of 1.8 but 17% above its last 4 quarters average of 1.2
Efficiency
How efficient is Leap Therapeutics business performance
The return on equity has increased by 28% year-on-year but it has declined by 21% since the previous quarter
The ROA has contracted by 19% from the previous quarter but it has grown by 12% YoY
Dividends
What is LPTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LPTX.
Financial health
How did Leap Therapeutics financials performed over time
LPTX's total liabilities is up by 48% from the previous quarter and by 33% YoY
The company's total assets rose by 40% QoQ but it fell by 15% YoY
LPTX's debt is 100% smaller than its equity
LPTX's debt has dropped by 75% since the previous quarter but it is up by 2.6% year-on-year
The equity has grown by 39% since the previous quarter but it has declined by 22% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.